Key Highlights
- bioAffinity Technologies shares closed up 21% at $0.47.
- The company partnered with SDVOSB AvMEDICAL to distribute CyPath Lung across federal healthcare networks.
- The deal includes access to VA medical centers via government procurement.
- Financial terms of the Partnership were not disclosed.
bioAffinity Technologies, Inc. (NASDAQ: BIAF) shares closed up 21% at $0.47 after the company partnered with SDVOSB AvMEDICAL to distribute CyPath Lung across federal healthcare networks, including VA medical centers.
What Happened
The partnership expands commercial access via government procurement channels, though the companies did not disclose financial terms of the arrangement.
Market Reaction
Shares rose as investors responded to the expanded distribution pathway into federal healthcare networks, viewing the government procurement channel as a meaningful new avenue for CyPath Lung's commercial reach.
Outlook
Continued expansion of CyPath Lung's access within VA medical centers and other federal healthcare networks is likely to remain relevant for bioAffinity Technologies' commercial trajectory going forward.
FAQs
Q: Why did bioAffinity Technologies shares rise 21%?
A: Shares rose after the company partnered with AvMEDICAL to distribute CyPath Lung across federal healthcare networks, including VA medical centers.
Q: Were financial terms of the partnership disclosed?
A: No, the companies did not disclose financial terms.
Q: What is CyPath Lung?
A: bioAffinity Technologies' diagnostic product now being distributed through federal healthcare procurement channels via AvMEDICAL.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.